Hearing impairment has emerged as a potential risk factor for Parkinson’s disease, a progressive neurodegenerative disorder that primarily manifests with motor impairments like tremors, rigidity, and ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Parkinson’s Disease has over 40 wide-ranging symptoms, as per the charity, from tremors and mental health issues to blood pressure changes. Those with Parkin 2 often experience these symptoms at ...

AI predicts Parkinson’s disease using medical and prescription data, enhancing early diagnosis and research into new ...

Advancing Light Therapy Research to Enhance Quality of Life for Parkinson's Patients This trial is important becau ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

21, 2025 — The B vitamin mitigates manganese neurotoxicity, which produces symptoms ... motor function, offering a new therapeutic ... A Risky Business: Why Do Some Parkinson's Disease ...

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...